Alzheimer’s drug reduces plaques, slows disease progression: full results
The amyloid-busting donanemab slowed clinical progression by 22-35% in early stages of condition, researchers say.
The monoclonal antibody donanemab slows clinical progression among patients with early symptomatic Alzheimer’s disease by up to a third compared to placebo, according to a study in JAMA.
Although the headline results were announced via a media statement in May, the full results of the TRAILBLAZER-ALZ 2 trial were published this week to coincide with the 2023 Alzheimer’s Association International Conference, held in Amsterdam, Netherlands.
